157 related articles for article (PubMed ID: 27798827)
1. Discovery of 2-((R)-4-(2-Fluoro-4-(methylsulfonyl)phenyl)-2-methylpiperazin-1-yl)-N-((1R,2s,3S,5S,7S)-5-hydroxyadamantan-2-yl)pyrimidine-4-carboxamide (SKI2852): A Highly Potent, Selective, and Orally Bioavailable Inhibitor of 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD1).
Ryu JH; Lee JA; Kim S; Shin YA; Yang J; Han HY; Son HJ; Kim YH; Sa JH; Kim JS; Lee J; Lee J; Park HG
J Med Chem; 2016 Nov; 59(22):10176-10189. PubMed ID: 27798827
[TBL] [Abstract][Full Text] [Related]
2. HIS-388, a novel orally active and long-acting 11β-hydroxysteroid dehydrogenase type 1 inhibitor, ameliorates insulin sensitivity and glucose intolerance in diet-induced obesity and nongenetic type 2 diabetic murine models.
Okazaki S; Takahashi T; Iwamura T; Nakaki J; Sekiya Y; Yagi M; Kumagai H; Sato M; Sakami S; Nitta A; Kawai K; Kainoh M
J Pharmacol Exp Ther; 2014 Oct; 351(1):181-9. PubMed ID: 25100752
[TBL] [Abstract][Full Text] [Related]
3. Discovery of Clinical Candidate 2-((2S,6S)-2-Phenyl-6-hydroxyadamantan-2-yl)-1-(3'-hydroxyazetidin-1-yl)ethanone [BMS-816336], an Orally Active Novel Selective 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor.
Ye XY; Chen SY; Wu S; Yoon DS; Wang H; Hong Z; O'Connor SP; Li J; Li JJ; Kennedy LJ; Walker SJ; Nayeem A; Sheriff S; Camac DM; Ramamurthy V; Morin PE; Zebo R; Taylor JR; Morgan NN; Ponticiello RP; Harrity T; Apedo A; Golla R; Seethala R; Wang M; Harper TW; Sleczka BG; He B; Kirby M; Leahy DK; Li J; Hanson RL; Guo Z; Li YX; DiMarco JD; Scaringe R; Maxwell B; Moulin F; Barrish JC; Gordon DA; Robl JA
J Med Chem; 2017 Jun; 60(12):4932-4948. PubMed ID: 28537398
[TBL] [Abstract][Full Text] [Related]
4. A novel highly potent and selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor, UI-1499.
Byun SY; Shin YJ; Nam KY; Hong SP; Ahn SK
Life Sci; 2015 Jan; 120():1-7. PubMed ID: 25447448
[TBL] [Abstract][Full Text] [Related]
5. A potent and selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor, SKI2852, ameliorates metabolic syndrome in diabetic mice models.
Oh H; Jeong KH; Han HY; Son HJ; Kim SS; Lee HJ; Kim S; Sa JH; Jun HS; Ryu JH; Choi CS
Eur J Pharmacol; 2015 Dec; 768():139-48. PubMed ID: 26519792
[TBL] [Abstract][Full Text] [Related]
6. Discovery and Biological Evaluation of Potent and Orally Active Human 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitors for the Treatment of Type 2 Diabetes Mellitus.
Koike T; Shiraki R; Sasuga D; Hosaka M; Kawano T; Fukudome H; Kurosawa K; Moritomo A; Mimasu S; Ishii H; Yoshimura S
Chem Pharm Bull (Tokyo); 2019; 67(8):824-838. PubMed ID: 31366832
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and optimization of picolinamide derivatives as a novel class of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors.
Ryu JH; Kim S; Lee JA; Han HY; Son HJ; Lee HJ; Kim YH; Kim JS; Park HG
Bioorg Med Chem Lett; 2015 Apr; 25(8):1679-1683. PubMed ID: 25800116
[TBL] [Abstract][Full Text] [Related]
8. Adamantyl carboxamides and acetamides as potent human 11β-hydroxysteroid dehydrogenase type 1 inhibitors.
Su X; Halem HA; Thomas MP; Moutrille C; Culler MD; Vicker N; Potter BV
Bioorg Med Chem; 2012 Nov; 20(21):6394-402. PubMed ID: 23040895
[TBL] [Abstract][Full Text] [Related]
9. A novel highly potent and selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor, INU-101.
Hong SP; Han D; Chang KH; Ahn SK
Eur J Pharmacol; 2018 Sep; 835():169-178. PubMed ID: 30096297
[TBL] [Abstract][Full Text] [Related]
10. Anti-diabetic and anti-adipogenic effects of a novel selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor in the diet-induced obese mice.
Park JS; Rhee SD; Jung WH; Kang NS; Kim HY; Kang SK; Ahn JH; Kim KY
Eur J Pharmacol; 2012 Sep; 691(1-3):19-27. PubMed ID: 22760069
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and structure-activity relationship of 2-adamantylmethyl tetrazoles as potent and selective inhibitors of human 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1).
Ye XY; Yoon D; Chen SY; Nayeem A; Golla R; Seethala R; Wang M; Harper T; Sleczka BG; Apedo A; Li YX; He B; Kirby M; Gordon DA; Robl JA
Bioorg Med Chem Lett; 2014 Jan; 24(2):654-60. PubMed ID: 24360604
[TBL] [Abstract][Full Text] [Related]
12. The development and SAR of pyrrolidine carboxamide 11beta-HSD1 inhibitors.
Cheng H; Hoffman J; Le P; Nair SK; Cripps S; Matthews J; Smith C; Yang M; Kupchinsky S; Dress K; Edwards M; Cole B; Walters E; Loh C; Ermolieff J; Fanjul A; Bhat GB; Herrera J; Pauly T; Hosea N; Paderes G; Rejto P
Bioorg Med Chem Lett; 2010 May; 20(9):2897-902. PubMed ID: 20363126
[TBL] [Abstract][Full Text] [Related]
13. Discovery and biological evaluation of adamantyl amide 11beta-HSD1 inhibitors.
Webster SP; Ward P; Binnie M; Craigie E; McConnell KM; Sooy K; Vinter A; Seckl JR; Walker BR
Bioorg Med Chem Lett; 2007 May; 17(10):2838-43. PubMed ID: 17350260
[TBL] [Abstract][Full Text] [Related]
14. Discovery of adamantyl ethanone derivatives as potent 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) inhibitors.
Su X; Pradaux-Caggiano F; Thomas MP; Szeto MW; Halem HA; Culler MD; Vicker N; Potter BV
ChemMedChem; 2010 Jul; 5(7):1026-44. PubMed ID: 20486152
[TBL] [Abstract][Full Text] [Related]
15. Novel 11β-HSD1 inhibitors: C-1 versus C-2 substitution and effect of the introduction of an oxygen atom in the adamantane scaffold.
Leiva R; Seira C; McBride A; Binnie M; Luque FJ; Bidon-Chanal A; Webster SP; Vázquez S
Bioorg Med Chem Lett; 2015 Oct; 25(19):4250-3. PubMed ID: 26306982
[TBL] [Abstract][Full Text] [Related]
16. Discovery of a potent, selective, and orally bioavailable acidic 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor: discovery of 2-[(3S)-1-[5-(cyclohexylcarbamoyl)-6-propylsulfanylpyridin-2-yl]-3-piperidyl]acetic acid (AZD4017).
Scott JS; Bowker SS; Deschoolmeester J; Gerhardt S; Hargreaves D; Kilgour E; Lloyd A; Mayers RM; McCoull W; Newcombe NJ; Ogg D; Packer MJ; Rees A; Revill J; Schofield P; Selmi N; Swales JG; Whittamore PR
J Med Chem; 2012 Jun; 55(12):5951-64. PubMed ID: 22691057
[TBL] [Abstract][Full Text] [Related]
17. Searching for novel applications of the benzohomoadamantane scaffold in medicinal chemistry: Synthesis of novel 11β-HSD1 inhibitors.
Valverde E; Seira C; McBride A; Binnie M; Luque FJ; Webster SP; Bidon-Chanal A; Vázquez S
Bioorg Med Chem; 2015 Dec; 23(24):7607-17. PubMed ID: 26596711
[TBL] [Abstract][Full Text] [Related]
18. Adamantyl ethanone pyridyl derivatives: potent and selective inhibitors of human 11β-hydroxysteroid dehydrogenase type 1.
Su X; Pradaux-Caggiano F; Vicker N; Thomas MP; Halem H; Culler MD; Potter BV
ChemMedChem; 2011 Sep; 6(9):1616-29. PubMed ID: 21714097
[TBL] [Abstract][Full Text] [Related]
19. Protective effect of a novel selective 11β-HSD1 inhibitor on eye ischemia-reperfusion induced glaucoma.
Choi KJ; Na YJ; Jung WH; Park SB; Kang S; Nam HJ; Ahn JH; Kim KY
Biochem Pharmacol; 2019 Nov; 169():113632. PubMed ID: 31494147
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and 11β hydroxysteroid dehydrogenase 1 inhibition of thiazolidine derivatives with an adamantyl group.
Kwon SW; Kang SK; Lee JH; Bok JH; Kim CH; Dal Rhee S; Jung WH; Kim HY; Bae MA; Song JS; Ha DC; Cheon HG; Kim KY; Ahn JH
Bioorg Med Chem Lett; 2011 Jan; 21(1):435-9. PubMed ID: 21093259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
